MSLN and cholestasis: In support, human MSLN+THY1+αSMA+ aPFs isolated from graft livers with cholestasis which were declined for transplantation were shown to express aPF-specific markers UPK1b, CD200, EMILIN2, BNC1, ASPN, GPC3, and GREM1, similar to that observed in mouse aPFs, suggesting MSLN-expressing aPFs are significant contributors to human cholestatic fibrosis and a potential target of anti-fibrotic therapy [17].